Fintel reports that on July 12, 2023, Needham maintained coverage of RxSight (NASDAQ:RXST) with a Buy recommendation.
Analyst Price Forecast Suggests 9.80% Downside
As of July 6, 2023, the average one-year price target for RxSight is 27.74. The forecasts range from a low of 24.24 to a high of $30.45. The average price target represents a decrease of 9.80% from its latest reported closing price of 30.76.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for RxSight is 82MM, an increase of 41.75%. The projected annual non-GAAP EPS is -2.25.
What is the Fund Sentiment?
There are 182 funds or institutions reporting positions in RxSight. This is an increase of 31 owner(s) or 20.53% in the last quarter. Average portfolio weight of all funds dedicated to RXST is 0.07%, an increase of 141.26%. Total shares owned by institutions increased in the last three months by 90.93% to 19,131K shares. 
The put/call ratio of RXST is 0.02, indicating a bullish outlook.
What are Other Shareholders Doing?
Ra Capital Management holds 3,053K shares representing 8.98% ownership of the company. No change in the last quarter.
Artisan Partners Limited Partnership holds 2,647K shares representing 7.79% ownership of the company.
ARTJX - Artisan International Small-Mid Fund Investor Shares holds 1,649K shares representing 4.85% ownership of the company.
Orbimed Advisors holds 1,203K shares representing 3.54% ownership of the company. No change in the last quarter.
Next Century Growth Investors holds 877K shares representing 2.58% ownership of the company. In it's prior filing, the firm reported owning 648K shares, representing an increase of 26.06%. The firm increased its portfolio allocation in RXST by 63.21% over the last quarter.
Additional reading:
- CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A P
- RxSIGHT, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) (In thousands, except share and per share amounts)
- RxSIGHT, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) (In thousands, except share and per share amounts)
- Amendment #2 to Sublease, dated as of January 16, 2023, by and between the
- Executive Incentive Compensation Plan
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
